Osiris Therapeutics (OSIR) 4.89 $OSIR
Osiris Provides Update Regarding NASDAQ Listing Status
GlobeNewswire - Fri Sep 16, 4:15PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company"
provided today an update concerning the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ".
OSIR: 4.89 (unch)
Osiris Provides Update Regarding NASDAQ Listing Matters
GlobeNewswire - Wed Aug 17, 4:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company" today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ".
OSIR: 4.89 (unch)
Osiris Therapeutics, Inc. (Nasdaq: OSIR) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Aug 05, 9:00AM CDT
What:
OSIR: 4.89 (unch), NDAQ: 70.44 (-0.23)
Grafix(R) Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon and Bone Clinical Trial is Available Electronically in Peer-Reviewed Journal
GlobeNewswire - Thu Aug 04, 3:33PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the manuscript from its multicenter prospective post-market clinical trial using Grafix was accepted for publication in the International Wound Journal, is now available online and will appear in an upcoming issue of the journal.
OSIR: 4.89 (unch)
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against Osiris Therapeutics, Inc. and Advises Investors to Contact the Firm
BusinessWire - Thu Jun 02, 11:49AM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Osiris Therapeutics, Inc. ("Osiris" or the "Company" (Nasdaq: OSIR). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
OSIR: 4.89 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company" (NASDAQ: OSIR) concerning possible violations of federal securities laws.
OSIR: 4.89 (unch), MDXG: 9.34 (+0.20)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
PR Newswire - Wed Jun 01, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company" (NasdaqGM: OSIR -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at
OSIR: 4.89 (unch)
INVESTOR ALERT: Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Tue May 31, 1:28PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Osiris Therapeutics, Inc. ("Osiris" or the "Company" (NASDAQ: OSIR) concerning the Company and its officers' possible violations of federal securities laws.
OSIR: 4.89 (unch)
MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 4.89 (unch), MDXG: 9.34 (+0.20)
Osiris to Present at the 26th European Wound Management Association Conference
BusinessWire - Tue May 10, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the 26th European Wound Management Association Conference.
OSIR: 4.89 (unch), SYK: 118.44 (+2.00)
Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix in "Real World" Study
BusinessWire - Mon May 02, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix(R) versus EpiFix(R).
OSIR: 4.89 (unch), SYK: 118.44 (+2.00)
Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 15.50 (+0.40), OSIR: 4.89 (unch), LGND: 118.16 (+1.20), ANIK: 47.99 (+0.06)
Shares of OSIR Down 63.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 04, 3:37PM CST
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 4 months, Osiris Therapeutics has returned 63.06% as of today's recent price of $6.20.
OSIR: 4.89 (unch)
Why Shares of Osiris Therapeutics Tanked Today
George Budwell, The Motley Fool - Motley Fool - Thu Feb 04, 10:15AM CST
What : Shares of the regenerative-medicine company Osiris Therapeutics fell by as much as 16% in early trading Thursday on modest volume after the company announced a major shake-up in its leadership team. Specifically, Dwayne Montgomery is taking...
OSIR: 4.89 (unch)
Osiris Therapeutics Announces Leadership Transition
BusinessWire - Wed Feb 03, 3:30PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Dwayne Montgomery, its current Chief Business Officer, has been appointed today to serve as Interim Chief Executive Officer. Frank Czworka, currently Vice President and General Manager of Wound Care, has been promoted to Chief Operating Officer. Mr. Montgomery will replace Dr. Lode Debrabandere who today has announced his resignation for personal reasons from Osiris.
OSIR: 4.89 (unch), SYK: 118.44 (+2.00)
Commit To Buy Osiris Therapeutics At $6, Earn 20% Annualized Using Options
StockOptionsChannel.com - Wed Feb 03, 10:53AM CST
Investors considering a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $7.01/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
OSIR: 4.89 (unch)
Osiris Provides Update Regarding NASDAQ Listing Status
GlobeNewswire - Fri Sep 16, 4:15PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company"
provided today an update concerning the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ". OSIR: 4.89 (unch)
Osiris Provides Update Regarding NASDAQ Listing Matters
GlobeNewswire - Wed Aug 17, 4:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company"
today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ". OSIR: 4.89 (unch)
Osiris Therapeutics, Inc. (Nasdaq: OSIR) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Aug 05, 9:00AM CDT
What:
OSIR: 4.89 (unch), NDAQ: 70.44 (-0.23)
Grafix(R) Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon and Bone Clinical Trial is Available Electronically in Peer-Reviewed Journal
GlobeNewswire - Thu Aug 04, 3:33PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the manuscript from its multicenter prospective post-market clinical trial using Grafix was accepted for publication in the International Wound Journal, is now available online and will appear in an upcoming issue of the journal.
OSIR: 4.89 (unch)
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against Osiris Therapeutics, Inc. and Advises Investors to Contact the Firm
BusinessWire - Thu Jun 02, 11:49AM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Osiris Therapeutics, Inc. ("Osiris" or the "Company"
(Nasdaq: OSIR). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. OSIR: 4.89 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company"
(NASDAQ: OSIR) concerning possible violations of federal securities laws. OSIR: 4.89 (unch), MDXG: 9.34 (+0.20)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
PR Newswire - Wed Jun 01, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company"
(NasdaqGM: OSIR -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at OSIR: 4.89 (unch)
INVESTOR ALERT: Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Tue May 31, 1:28PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Osiris Therapeutics, Inc. ("Osiris" or the "Company"
(NASDAQ: OSIR) concerning the Company and its officers' possible violations of federal securities laws. OSIR: 4.89 (unch)
MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 4.89 (unch), MDXG: 9.34 (+0.20)
Osiris to Present at the 26th European Wound Management Association Conference
BusinessWire - Tue May 10, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the 26th European Wound Management Association Conference.
OSIR: 4.89 (unch), SYK: 118.44 (+2.00)
Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix in "Real World" Study
BusinessWire - Mon May 02, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix(R) versus EpiFix(R).
OSIR: 4.89 (unch), SYK: 118.44 (+2.00)
Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 15.50 (+0.40), OSIR: 4.89 (unch), LGND: 118.16 (+1.20), ANIK: 47.99 (+0.06)
Shares of OSIR Down 63.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 04, 3:37PM CST
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 4 months, Osiris Therapeutics has returned 63.06% as of today's recent price of $6.20.
OSIR: 4.89 (unch)
Why Shares of Osiris Therapeutics Tanked Today
George Budwell, The Motley Fool - Motley Fool - Thu Feb 04, 10:15AM CST
What : Shares of the regenerative-medicine company Osiris Therapeutics fell by as much as 16% in early trading Thursday on modest volume after the company announced a major shake-up in its leadership team. Specifically, Dwayne Montgomery is taking...
OSIR: 4.89 (unch)
Osiris Therapeutics Announces Leadership Transition
BusinessWire - Wed Feb 03, 3:30PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Dwayne Montgomery, its current Chief Business Officer, has been appointed today to serve as Interim Chief Executive Officer. Frank Czworka, currently Vice President and General Manager of Wound Care, has been promoted to Chief Operating Officer. Mr. Montgomery will replace Dr. Lode Debrabandere who today has announced his resignation for personal reasons from Osiris.
OSIR: 4.89 (unch), SYK: 118.44 (+2.00)
Commit To Buy Osiris Therapeutics At $6, Earn 20% Annualized Using Options
StockOptionsChannel.com - Wed Feb 03, 10:53AM CST
Investors considering a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $7.01/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
OSIR: 4.89 (unch)
